These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8889281)

  • 41. The current status of PET scanning with respect to schizophrenia.
    Sedvall G
    Neuropsychopharmacology; 1992 Aug; 7(1):41-54. PubMed ID: 1388021
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vivo imaging of neurotransmission and brain receptors in dementia.
    Pappatà S; Salvatore E; Postiglione A
    J Neuroimaging; 2008 Apr; 18(2):111-24. PubMed ID: 18380693
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dementing conditions studied with PET.
    Leenders KL; Aquilonius SM
    J Neural Transm Suppl; 1987; 24():31-41. PubMed ID: 2890710
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro positron emission tomography (PET): use of positron emission tracers in functional imaging in living brain slices.
    Matsumura K; Bergström M; Onoe H; Takechi H; Westerberg G; Antoni G; Bjurling P; Jacobson GB; Långström B; Watanabe Y
    Neurosci Res; 1995 May; 22(2):219-29. PubMed ID: 7566703
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Applications of positron emission tomography in psychiatry.
    Parsey RV; Mann JJ
    Semin Nucl Med; 2003 Apr; 33(2):129-35. PubMed ID: 12756645
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies.
    Vegting Y; Reneman L; Booij J
    Psychopharmacology (Berl); 2016 Oct; 233(19-20):3473-501. PubMed ID: 27568200
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PET: its clinical role in neurology.
    Brooks D
    J Neurol Neurosurg Psychiatry; 1991 Jan; 54(1):1-5. PubMed ID: 1672706
    [No Abstract]   [Full Text] [Related]  

  • 48. Imaging the neurochemistry of nicotine actions: studies with positron emission tomography.
    Volkow ND; Fowler JS; Ding YS; Wang GJ; Gatley SJ
    Nicotine Tob Res; 1999; 1 Suppl 2():S127-32; discussion S139-40. PubMed ID: 11768169
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review.
    Laruelle M
    J Cereb Blood Flow Metab; 2000 Mar; 20(3):423-51. PubMed ID: 10724107
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regional brain glucose metabolism in drug free schizophrenic patients and clinical correlates.
    Wiesel FA; Wik G; Sjögren I; Blomqvist G; Greitz T; Stone-Elander S
    Acta Psychiatr Scand; 1987 Dec; 76(6):628-41. PubMed ID: 3502060
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Positron emission tomography and brain monoamine neurotransmission -- entries for study of drug interactions.
    Hartvig P; Bergström M; Antoni G; Langstrom B
    Curr Pharm Des; 2002; 8(16):1417-34. PubMed ID: 12052204
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular imaging in neuroscience research with small-animal PET in rodents.
    Xi W; Tian M; Zhang H
    Neurosci Res; 2011 Jun; 70(2):133-43. PubMed ID: 21241748
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia.
    Volkow ND; Ding YS; Fowler JS; Gatley SJ
    Biol Psychiatry; 2001 Feb; 49(3):211-20. PubMed ID: 11230872
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neuroimaging in epilepsy: recent developments in MR imaging, positron-emission tomography, and single-photon emission tomography.
    Sperling MR
    Neurol Clin; 1993 Nov; 11(4):883-903. PubMed ID: 8272037
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Implications of positron emission tomography research for the investigation of the actions of antipsychotic drugs.
    List SJ; Cleghorn JM
    Br J Psychiatry Suppl; 1993 Dec; (22):25-30. PubMed ID: 7906522
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Clinical positron emission tomography: brain imaging].
    Borbély K
    Orv Hetil; 2002 May; 143(21 Suppl 3):1294-7. PubMed ID: 12077920
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Flumazenil positron emission tomography and other ligands for functional imaging.
    Hammers A
    Neuroimaging Clin N Am; 2004 Aug; 14(3):537-51. PubMed ID: 15324863
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Neurotransmitter-receptor-imaging].
    Cordes M; Hierholzer J; Nikolai-Beyer K
    Radiologe; 1993 Nov; 33(11):612-9. PubMed ID: 7904078
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Positron emission tomography: ligand imaging.
    Moghbel M; Newberg A; Alavi A
    Handb Clin Neurol; 2016; 135():229-240. PubMed ID: 27432668
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PET studies with carbon-11 radioligands in neuropsychopharmacological drug development.
    Halldin C; Gulyás B; Farde L
    Curr Pharm Des; 2001 Dec; 7(18):1907-29. PubMed ID: 11772357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.